SCABIES – PRACTICAL RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT
Introduction: Scabies is an infection caused by the parasite Sarcoptes scabiei var. hoministhat gains significance due to the morbidity associated with intense itching, high infectivity, frequent outbreaks and persistence of symptoms for many days even after complete eradication.
Objectives: Approach to pathophysiology, differential diagnosis and treatment options in children.
Development: In pediatrics the differential diagnosis of escabiosis with other very common diseases in this age group is sometimes diffi cult. The lack of studies regarding effi cacy and safety of the various available drugs in children makes it diffi cult to drawn recommendations. Scabies treatment is based more on personal experience, local availability and cost than on medical evidence.
Conclusions: This article aims to summarize the pathogenesis of infection by Sarcoptes scabiei var. hominis in children focusing special attention on symptoms and treatment. Although there are no randomized controlled trials with sulfur precipitated in scabies treatment to prove its effi cacy and safety, it seems to be one of the most recommended drugs in this age group.
Karthikeyan K. Scabies in children. Arch Dis Child Educ Pract
Ed 2007; 92:ep65 -9.
Chosidow O. Clinical practices. Scabies. N Engl J Med 2006;
Esteves JA, Baptista AP, Rodrigo EG, Gomes MA. Dermatologia.
ª edição. Fundação Calouste Gulbenkian, 2005:
Wolf R, Davidovici B. Treatment of scabies and pediculosis:
facts and controversies. Clin Dermatol 2010; 28:511 -8.
Leone PA. Scabies and pediculosis pubis: an update of treatment
regimens and general review. Clin Infect Dis 2007;
Walton SF, Currie BJ. Problems in diagnosing scabies, a global
disease in human and animal populations. Clin Microbiol
Rev 2007; 20:268 -79.
Chosidow O. Scabies and pediculosis. Lancet 2000; 355:819-
Eichenfi eld L, Frieden I, Esterly N. Neonatal Dermatology. 2th
ed. Saunders Elsevier, 2008: 220 -2.
Johnston G, Sladden M. Scabies: diagnosis and treatment.
BMJ 2005; 331:619 -22.
Global Health - Division of Parasitic Diseases and Malaria.
Parasites - Scabies - Treatment. Centers for Disease Control
and Prevention 2010 (Acedido em: 6 Março 2012). Disponível
Scott GR, Chosidow O; IUSTI/WHO. European guideline
for the management of scabies, 2010. Int J STD AIDS 2011;
Heukelbach J, Feldmeier H. Scabies. Lancet 2006; 367:1767-
Prendiville J. Scabies and Lice. In: Harper J, Oranje A, Prose
N. Harper’s Textbook of Pediatric Dermatology 2nd Ed.
Blackwell Publishing Lt 2005. p 555 -62.
Goldstein B, Goldstein A. Scabies 2012 (Acedido em: 6 Março
. Disponível em: http://www.uptodate.com/contents/
Jin SP, Choi JE, Won CH, Cho S. Scabies in a 2 -month -old
Infant Successfully Treated with Lindane. Ann Dermatol 2009;
Strong M, Johnstone P. Interventions for treating scabies. Cochrane
Database Syst Rev 2007; 3:CD000320.
Walker GJ, Johnstone PW. Interventions for treating scabies.
Cochrane Database Syst Rev 2000; 3:CD000320.
Arlian LG, Runyan RA, Achar S, Estes SA. Survival and infectivity
of Sarcoptes scabiei var. canis and var. hominis. J Am
Acad Dermatol 1984; 11:210 -5.
Karthikeyan K. Treatment of scabies: newer perspectives.
Postgrad Med J 2005; 81:7 -11.
Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate
for childhood scabies in developing countries. J Paediatr
Child Health 2002; 38:401 -4.
Caramona M, Esteves A, Gonçalves J, Macedo T, Mendonça
J, Walter O, et al. Prontuário terapêutico 2011. Medicamentos
usados em afecções cutâneas. Antiparasitários. Sarcoptose
(Sarcoptes scabiei - sarna): 444 -5.
Zargari O, Golchai J, Sobhani A, Dehpour AR, Sadr -Ashkevari
S, Alizadeh N, Darjani A. Comparison of the effi cacy of topical
% lindane vs 5% permethrin in scabies: a randomized,
double -blind study. Indian J Dermatol Venereol Leprol 2006;
Singalavanija S, Limpongsanurak W, Soponsakunkul S. A
comparative study between 10 per cent sulfur ointment and
3 per cent gamma benzene hexachloride gel in the treatment
of scabies in children. J Med Assoc Thai 2003; 86:S531-
Ishii N, Asahina A, Amagai M, Iijima M, Ishikawa O, Imamura
H, et al. Guideline for the diagnosis and treatment of scabies
in Japan (second edition). J Dermatol 2008; 35:378 -93.
Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade
VP, Dakhale GN. Comparison of safety, effi cacy, and cost
effectiveness of benzyl benzoate, permethrin, and ivermectin
in patients of scabies. Indian J Pharmacol 2009; 41:9 -14.
Briones V. Escabiosis. Protocolos de Dermatología. Asociación
Española de Pediatría. 2008: 159 -63 (Acedido em: 6 Março
. Disponível em: http://www.aeped.es/sites/default/
Cook AM, Romanelli F. Ivermectin for the treatment of resistant
scabies. Ann Pharmacother 2003; 37:279 -81.
Buffet M, Dupin N. Current treatments for scabies. Fundam
Clin Pharmacol 2003; 17:217 -25.
Guay DR. The scourge of sarcoptes: oral ivermectin for scabies.
Consult Pharm 2004; 19:222 -35.
Usha V, Gopalakrishnan Nair TV. A comparative study of oral
ivermectin and topical permethrin cream in the treatment of
scabies. J Am Acad Dermatol 2000; 42:236 -40.
Sharma R, Singal A. Topical permethrin and oral ivermectin in
the management of scabies: a prospective, randomized, double
blind, controlled study. Indian J Dermatol Venereol Leprol
; 77:581 -6.
Goldstein B, Goldstein A. Patients information: Scabies 2012
(Acedido em: 6 Março 2012). Disponível: http://www.uptodate.
com/contents/patient -information -scabies
Díaz M, Cazorla D, Acosta M. Effi cacy, safety and acceptability
of precipitated sulphur petrolatum for topical treatment
of scabies at the city of Coro, Falcon State, Venezuela. Rev
Invest Clin 2004; 56:615 -22.
Scabies management. Ottawa, ON: Canadian Paediatric Society.
(Acedido em: 30 Março 2012). Disponível em:
Copyright (c) 2017 NASCER E CRESCER
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright and access
This journal offers immediate free access to its content, following the principle that providing free scientific knowledge to the public provides greater global democratization of knowledge.
The works are licensed under a Creative Commons Attribution Non-commercial 4.0 International license.
Nascer e Crescer – Birth and Growth Medical Journal do not charge any submission or processing fee to the articles submitted.